Also, for WHO grade III and IV tumors, patients with IDH mutant tumors have been shown to benefit from extended resection (encompassing both enhancing and non-enhancing tumor) as opposed to those with an IDH wildtype tumor14. Here, IDH2 is linked to neoplasm.